Carboplatin

Carboplatin is a platinum-based chemotherapy drug used to treat several cancers linked to asbestos exposure, including malignant pleural mesothelioma and non-small cell lung cancer. It works by binding to the DNA inside cancer cells, creating damage the cells cannot repair, which leads them to die. It is typically given by intravenous infusion every three weeks as part of a combination regimen.

Origin

Carboplatin was developed in the late 1970s at the Institute of Cancer Research in London as a less toxic alternative to cisplatin. The name reflects its chemistry: a platinum atom bonded to a carbon-containing cyclobutanedicarboxylate group. The U.S. FDA approved it in 1989.

Significance in Asbestos Context

Carboplatin is one of the most commonly used chemotherapy drugs for patients with asbestos-related cancers. For mesothelioma, it is usually combined with pemetrexed (Alimta), sometimes with the addition of bevacizumab (Avastin) or immunotherapy. For asbestos-related lung cancer, it is often paired with paclitaxel, gemcitabine, or pemetrexed. From a legal standpoint, records of carboplatin treatment (infusion dates, dosing, lab results, side effects, and hospitalizations) document both the seriousness of the disease and the physical burden of treatment. These records support compensation for medical expenses, pain and suffering, and loss of quality of life in lawsuits and bankruptcy trust claims. The choice of carboplatin over cisplatin is often made because the patient is older or has reduced kidney function, which is itself relevant context for damages.

Example Sentence

"After her mesothelioma diagnosis, she began a course of carboplatin and pemetrexed infusions every three weeks, and her oncologist monitored her blood counts closely between cycles."

Related Terms

Cisplatin, Pemetrexed (Alimta), Malignant Pleural Mesothelioma, Platinum-Based Doublet Therapy, Bevacizumab, Immunotherapy

Notes

• Ask your oncologist how your dose was calculated. Carboplatin is usually dosed by the Calvert formula, which is based on your kidney function (GFR), not just body size. Confirm that recent kidney labs were used.
• Watch for and promptly report low blood counts (unusual bruising, bleeding, fever, or extreme fatigue), allergic reactions during infusion (which become more common after several cycles), numbness or tingling in the hands and feet, and hearing changes.
• Keep a personal treatment log with infusion dates, doses, side effects, missed cycles, and hospitalizations. Request copies of your oncology notes, infusion records, and lab results. These documents are central evidence for both lawsuit damages and trust claim severity tiers.
• Ask whether you are a candidate for newer options or additions, such as bevacizumab or first-line immunotherapy with nivolumab plus ipilimumab (FDA-approved for unresectable mesothelioma in 2020), and whether a clinical trial is available.
• If side effects become intolerable, talk to your oncologist before stopping. Dose reductions, schedule changes, or switching to cisplatin or a different combination are common alternatives.